Emory launches new program to improve health equity by accelerating disease diagnostic research

December 18, 2023 | Saporta Report

Striving to ensure advanced medical technologies are reaching the populations who need them most,  Emory’s Center for the Advancement of Diagnostics for a Just Society  (ADJUST) is launching this year as part of NIH’s RADx program.

The last several years have demonstrated that new technologies are steadily allowing for the diffusion of disease diagnosis and monitoring out of clinical environments and into communities, businesses, schools, and homes. These types of point-of-care technologies offer numerous benefits, but they also introduce a whole new set of issues – not only technological and clinical, but also logistical, regulatory, commercial, social, and ethical. Often times, the patients who need these new technologies the most have the least access.

Emory’s new center is the first-of-its-kind designed to address these issues. Utilizing a two-pronged approach to accelerate diagnostic development while ensuring health equity and justice, the ADJUST Center will serve as both a thinktank focusing on the advancement of future disease diagnosis through research and advocacy, as well as a technology foundry to accelerate diagnostic development.

“Given our vast experience, expertise, and ecosystem in diagnostics, we are well poised to be the only center in the nation dedicated to advancing the entire field of diagnostics forward in this modern era of medicine,” says Wilbur Lam, MD, PhD, pediatric hematologist and oncologist at  Children’s Healthcare of Atlanta,   and professor of pediatrics and biomedical engineering at Emory University and Georgia Institute of Technology. “As we help develop and translate new diagnostic technologies, our Center will also concurrently address the issues of accessibility, usability, and affordability to ensure these state-of-art tests will serve the populations who need them the most.”

The ADJUST Center is borne out of the NIH-funded point-of-care technologies center, the  ACME POCT , which is one of six sites in the U.S. selected by NIH as part of the NIH Point-of-Care Technologies Research Network. ACME POCT played a pivotal role during the onset of the COVID-19 pandemic as the national test verification center to rapidly evaluate COVID-19 tests and help make them widely available.

The ADJUST Center will seek to build off the expertise compiled during the COVID-19 pandemic and apply the lessons learned and proven tactics to ensure equitable access to advanced technology for everyone. Projects already underway include assessing the potential adverse outcomes of consumer health wearable technologies and examining the availability of point-of-care HPV diagnostics.   

Emory’s Senior Vice President for Research Deborah Bruner, PhD, says, “The ADJUST Center is an important new initiative that builds upon Emory’s strengths and impacts so many of our institutional goals. It is highly innovative, it is entrepreneurial, it is collaborative, and it is focused on health equity – it encompasses a wide variety of things that make us Emory.  I’m extremely excited to see what the center can achieve for our community and the world.”

Source: https://saportareport.com/emory-launches-new-program-to-improve-health-equity-by-accelerating-disease-diagnostic-research/thought-leadership/higher-education/emory-university/

January 20, 2026
January 20, 2026. Paulding County has been designated a BioReady Silver Community by Georgia Life Sciences, the state’s leading life sciences membership organization. The BioReady designation recognizes communities that demonstrate strong zoning practices, infrastructure capacity, and readiness to support biotechnology and life sciences development. “We are proud to recognize Paulding County as our newest BioReady Silver community,” said Maria Thacker-Goethe, President and CEO of Georgia Life Sciences. “Paulding County’s proactive planning, growing workforce, and access to regional healthcare and transportation infrastructure position it well to support life sciences manufacturing and commercialization. Through the BioReady program, we champion communities that are intentionally preparing to compete for industry investment and job growth.” Paulding County’s designation reflects its commitment to thoughtful land-use planning, scalable infrastructure, and business-friendly development policies that support life sciences and advanced manufacturing uses. Located in the northwest Atlanta metro region, the county offers access to a strong labor pool, major transportation corridors, and regional healthcare systems, making it an attractive option for biotechnology, medical device, diagnostics, and related life sciences companies seeking room to grow. “Georgia BioReady designation validates Paulding County’s readiness to support bioscience investment and strengthens our position as a growing hub for advanced industries,” said Alex Almodovar, President & CEO, Paulding County Economic Development Inc. & Industrial Building Authority The BioReady rating system evaluates communities across three tiers—Bronze, Silver, and Gold—based on their readiness to attract and support life sciences facilities. Through these ratings, Georgia Life Sciences helps municipalities better showcase biotech-appropriate sites, strengthen infrastructure planning, and clearly identify life sciences-friendly locations. This approach enables communities like Paulding County to compete more effectively for private investment and high-quality job creation. Georgia Life Sciences advances innovation, strengthens the workforce pipeline, and grows Georgia’s life sciences economy through the BioReady Community program, modeled after MassBio’s nationally recognized rating system, which assesses a community’s readiness to host life sciences facilities based on zoning practices and infrastructure capacity. About Georgia Life Sciences Georgia Life Sciences, founded in 1989, is a non-profit, membership-based organization that promotes the interests and growth of the life sciences industry. It is the state’s largest and most influential life sciences advocacy and business leadership organization working to improve access to innovative discoveries that have lifesaving impact. The association connects business, academia, government, and other allied entities involved in the application of life sciences products to fuel growth and collaboration through policy development, community programs, national industry initiatives, and a portfolio of educational and networking events. Learn more at galifesciences.org.
January 14, 2026
What happens when students see real work before choosing a future 
January 8, 2026
By: Patrick Plues | RealClearHealth January 8, 2026 For decades, America has led the global biotech industry – thanks, in part, to state-level policies that encourage research and manufacturing investments. But other countries, including China, are sparing no expense in the bid to overtake us. Beijing has officially made biotechnology a national strategic priority and is pouring billions into state-backed research and manufacturing efforts. All states should consider impactful biotech policies that grow and strengthen our domestic biotechnology industry. If states fail to utilize and replicate what are considered to be the best and most successful policies in biotech-focused economic development, the United States will soon lose its long-term leadership in developing medicines and medical technologies, which underpin our health, our economy, and our national security. Thankfully, many governors and state legislatures around the country are already answering this call -- as our new study, The U.S. Bioscience Industry: A Powerful Engine for State Economies, demonstrates. Keep Reading at https://www.realclearhealth.com/2026/01/08/americas_biotech_leadership_depends_on_the_states_1157584.html
MORE POSTS